Evidence map›Paper›PMID 30366371›Full record

ArticleJournal of clinical medicine2018

Clinical Utility of Definitive Drug⁻Drug Interaction Testing in Primary Care.

John Peabody, Mary Tran, David Paculdo, Joshua Schrecker, Czarlota Valdenor, Elaine Jeter

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John PeabodyDepartment of Epidemiology and Biostatistics/Department of Medicine, University of California, San Francisco, CA 94158, USA. jpeabody@qurehealthcare.com.ORCID 0000-0002-0210-9232
Mary TranQURE Healthcare, San Francisco, CA 94133, USA. mtran@qurehealthcare.com.
David PaculdoQURE Healthcare, San Francisco, CA 94133, USA. dpaculdo@qurehealthcare.com.
Joshua SchreckerAegis Sciences Corporation, Nashville, TN 37228, USA. joshua.schrecker@aegislabs.com.ORCID 0000-0002-9731-123X
Czarlota ValdenorQURE Healthcare, San Francisco, CA 94133, USA. czarlie@qurehealthcare.com.
Elaine JeterAegis Sciences Corporation, Nashville, TN 37228, USA. elaine.jeter@aegislabs.com.
AEgis Technologies (United States) · USUniversity of California, Los Angeles · US

Funding

Aegis Sciences Corporation N/A
6 · The paper itself

Abstract

Drug⁻drug interactions (DDIs) are a leading cause of morbidity and mortality. New tools are needed to improve identification and treatment of DDIs. We conducted a randomized controlled trial to assess the clinical utility of a new test to identify DDIs and improve their management. Primary care physicians (PCPs) cared for simulated patients presenting with DDI symptoms from commonly prescribed medications and other ingestants. All physicians, in either control or one of two intervention groups, cared for six patients over two rounds of assessment. Intervention physicians were educated on the DDI test and given access to these test reports when caring for their patients in the second round. At baseline, we saw no significant differences in making the DDI diagnosis (

Indexed as

adverse drug eventCNS depressantsdrug–drug interactiondrug–food interactiondrug–supplement interactionmedication reconciliationopioidsprimary carepsychiatric medications

Identifiers

PMID30366371
PMCPMC6262337
OpenAlexW2898125463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.